The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMc Mining Regulatory News (MCM)

Share Price Information for Mc Mining (MCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.00
Bid: 7.50
Ask: 8.50
Change: 0.00 (0.00%)
Spread: 1.00 (13.333%)
Open: 8.00
High: 8.00
Low: 7.75
Prev. Close: 8.00
MCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Receipt of Notice of Intention to Make a Takeover

2 Nov 2023 13:15

RNS Number : 2322S
MC Mining Limited
02 November 2023
 

ANNOUNCEMENT 2 November 2023

 

RECEIPT OF NOTICE OF INTENTION TO MAKE A TAKEOVER - TAKE NO ACTION

MC Mining Limited (MCM or the Company) has received a letter dated 1 November 2023 (Proposal Letter) from Senosi Group Investment Holdings Proprietary Limited and Dendocept Proprietary Limited, each substantial shareholders of the Company, sent on behalf of shareholders and associates stated to represent in aggregate 64.5%[1] of the issued capital in the Company (together, the Consortium).

 

The Proposal Letter outlines the Consortium's proposal and intention to make an off-market cash takeover offer for all the shares in the Company not currently held by the Consortium (Proposed Takeover). The Proposal Letter also states that the Consortium has made an application to the Australian Securities & Investments Commission (ASIC) under section 655A(1) of the Corporations Act 2001 (Cth) (Act), seeking relief from section 606 of the Act to permit the Consortium to enter into a joint bidding agreement for the purposes of undertaking a joint takeover bid for the Company.

 

The Proposal Letter refers to the Consortium's earlier confidential and incomplete, non-binding, conditional and indicative offer dated 5 September 2023 from Senosi Group Investment Holdings Proprietary Limited and Dendocept Proprietary Limited (NBIO). The NBIO set out indicative but incomplete details of a proposed takeover by Senosi Group Investment Holdings Proprietary Limited and Dendocept Proprietary Limited, including an indicative cash consideration offer range of AUD$0.20-AUD$0.23 per ordinary share, based on the Company's undiluted share capital. The NBIO proposal was subject to a number of conditions, including third party and regulatory approvals. In its Proposal Letter, the Consortium has also stated that it is its ''present intention that it will be a condition of the bid that no convertible securities vest as a result of the bid''.

 

Following the receipt of the NBIO, the Company established an Independent Board Committee (IBC) to consider the NBIO on behalf of shareholders not associated with the Consortium and to seek to evaluate and improve the indicative offer price. The IBC members comprise Mr Khomotso Mosehla, Mr Nhlanhla Nene, Mr Andrew Mifflin and Mr Julian Hoskin, being the Company's directors other than Ms Yi (Christine) He and Mr Ontiretse Mathews Senosi, who are representatives of the Consortium. Other directors associated with the Consortium and not included in the IBC are Mr An Chee Sin and Mr Zhen Brian He. Mr Godfrey Gomwe, the Chief Executive Officer of the Company, is an invitee of the IBC.

 

The IBC has been evaluating the indicative terms of the NBIO, including taking advice from its financial and Australian and South African legal advisors. Adelaide Equity Advisors as Financial Advisor, K&L Gates as Australian Legal Advisor and each of Webber Wentzel and Falcon & Hume, as South African Legal Advisors have been engaged by the IBC.

Whilst the Consortium's Proposal Letter notifies the Company of an intention and proposal to make a takeover offer for the purposes of ASX Listing Rule 7.9[2], it does not yet provide a definitive offer price for the Proposed Takeover. The progress of the Proposed Takeover is also subject to the Consortium obtaining regulatory relief from ASIC.

 

Accordingly, the IBC advises shareholders to TAKE NO ACTION at this stage in relation to the Proposed Takeover, until they receive further guidance from the IBC. A further announcement will be made by the Company as and when more complete and definitive details are received.

 

Khomotso Mosehla

Chairman of the IBC

 

This announcement has been approved by the Company's Disclosure Committee.

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended.

 

 

For more information contact:

 

 

Tony Bevan

Company Secretary

Endeavour Corporate Services

+61 8 9316 9100

 

Company advisors:

 

Richard Johnson / Rob Patrick

Nominated Adviser

Strand Hanson Limited

+44 20 7409 3494

 

Rory Scott

 

Broker (AIM)

Tennyson Securities

+44 20 7186 9031

 

Marion Brower

Financial PR (South Africa)

R&A Strategic Communications

+27 11 880 3924

 

BSM Sponsors Proprietary Limited is the nominated JSE Sponsor

 

About MC Mining Limited:

 

MC Mining is an AIM/ASX/JSE-listed coal exploration, development and mining company operating in South Africa. MC Mining's key projects include the Uitkomst Colliery (steelmaking and thermal coal), Makhado Project (steelmaking hard coking coal), Vele Colliery (steelmaking semi-soft coking and thermal coal), and the Greater Soutpansberg Projects (steelmaking coking and thermal coal).

 

 


[1] As at the date of this announcement, Senosi Group Investment Holdings (Pty) Limited holds 23.4% and Dendocept Proprietary Limited holds 6.9% of the current issued capital of the Company.

[2] This rule places a three month restriction on a target takeover entity from issuing equity securities without shareholder approval, subject to certain exceptions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBDBDBDUGDGXD
Date   Source Headline
29th Jul 202210:00 amRNSActivities Report for the Quarter Ended 30 Jun 22
28th Jul 202211:25 amRNSStatement Re Share Price Movement
28th Jul 202211:21 amRNSUitkomst Coal Sales & Marketing Agreement
27th Jul 20224:41 pmRNSSecond Price Monitoring Extn
27th Jul 20224:35 pmRNSPrice Monitoring Extension
15th Jul 202212:15 pmRNSResult of Extraordinary General Meeting
15th Jun 20224:25 pmRNSDespatch of Notice of General Meeting
6th Jun 202212:52 pmRNSStandby Loan Facility
17th May 20227:00 amRNSIssue of Shares Under Performance Rights Plan
29th Apr 20228:01 amRNSAppendix 5B
29th Apr 20228:00 amRNSActivities Report for the Quarter Ended 31 Mar 22
28th Apr 20227:00 amRNSChanges to the Board
14th Apr 20222:05 pmRNSSecond Price Monitoring Extn
14th Apr 20222:00 pmRNSPrice Monitoring Extension
14th Apr 202211:00 amRNSPrice Monitoring Extension
13th Apr 20224:40 pmRNSSecond Price Monitoring Extn
13th Apr 20224:35 pmRNSPrice Monitoring Extension
13th Apr 202212:54 pmRNSMakhado Bankable Feasibility Study Completed
11th Apr 20226:22 pmRNSREPLACEMENT:Results of EGM & Election of Directors
11th Apr 20224:57 pmRNSResults of EGM & Election of Directors
8th Apr 20222:30 pmRNSResignation of Executive Director
6th Apr 20224:18 pmRNSIssue of First Tranche Shares and TVR
17th Mar 20224:41 pmRNSSecond Price Monitoring Extn
17th Mar 20224:36 pmRNSPrice Monitoring Extension
14th Mar 20227:00 amRNSInterim Financial Report
14th Mar 20227:00 amRNSHalf-year Results
11th Mar 20227:00 amRNSResignation of Non-Executive Chairman
8th Mar 20222:23 pmRNSHolding(s) in Company
4th Mar 20229:59 amRNSDespatch Notice of Extraordinary General Meeting
1st Mar 20229:10 amRNSCompany Update
22nd Feb 20223:57 pmRNSHolding(s) in Company
14th Feb 20227:00 amRNSNotice Received Under Section 249D
1st Feb 20227:00 amRNSCapital Raising US$5.6 million
31st Jan 20227:24 amRNSActivities Report for the Quarter Ended 31 Dec 21
31st Jan 20227:23 amRNSAppendix 5B
28th Jan 20224:08 pmRNSIDC Loan Update
17th Jan 20223:43 pmRNSGrant of Performance Rights to Directors
11th Jan 20227:00 amRNSMakhado Project Update
14th Dec 20212:38 pmRNSBoard Changes
14th Dec 20212:35 pmRNSResult of Annual General Meeting
16th Nov 20217:00 amRNSDespatch of Notice of AGM
29th Oct 20212:45 pmRNSDespatch of Annual Report
29th Oct 202110:26 amRNSAppendix 5B
29th Oct 202110:25 amRNSReport for the Quarter Ended 30 September 2021
22nd Oct 202111:15 amRNSHolding(s) in Company
20th Oct 202110:30 amRNSHolding(s) in Company
19th Oct 20212:26 pmRNSAnnual General Meeting Details
8th Oct 20217:30 amRNSHolding(s) in Company
30th Sep 20216:01 pmRNSAnnual Financial Report
30th Sep 20216:00 pmRNSResults for the Full Year Ended 30 June 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.